Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) (Pegade)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 10, 2005
Last updated: October 1, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)